Objective: Atrial remodeling contributes to the maintenance of atrial fibrillation (AF) in several cardiac disorders. There is evidence that angiotensin-converting enzyme (ACE) inhibitors reduce the prevalence of AF in patients with congestive heart failure (CHF). There have been no studies performed to assess the effects of ACE inhibitors on atrial dimensions and emptying function in relationship to vulnerability to AF in the setting of experimental CHF. Methods: CHF was produced in 20 dogs by rapid right ventricular pacing during 5 weeks. The dogs were randomized to enalapril (EN) therapy (2 mg / kg / day, n510) or to a control group (n510). Echocardiography was performed at baseline and weekly thereafter. At the 5-week electrophysiological study, AF was induced by burst pacing and AF duration was measured. Results: Atrial areas increased significantly with CHF. Left atrial (LA) fractional area shortening (FAS) decreased by 42% (P50.0001) in controls but by 9% (P5NS) in the EN group (P50.01, EN vs. controls). Similar findings were observed for right atrial (RA) changes (P50.02). Atrial fibrosis was highly correlated with the decrease in LA FAS (r50.85, P,0.01) and was reduced by EN (from 11.261.6 to 8.360.7%, P50.008). AF duration was 7206461 s for controls and 138683 s for EN (P50.001). LA and RA areas and FAS at 5 weeks correlated with AF duration (P#0.001 for all). FAS decrease in both atria also correlated with AF duration at follow-up (r50.78 and 0.77 for LA and RA, P#0.001 for both). Conclusions: Experimental CHF causes structural and functional abnormalities in both atria, which are correlated with AF duration. ACE inhibition attenuates CHF-induced atrial fibrosis and remodeling and reduces associated AF promotion. These results indicate a role for the renin-angiotensin system in arrhythmogenic atrial structural remodeling in CHF.
Introduction
changes, including extensive interstitial fibrosis, enlargement and hypertrophy [6, 8] . This atrial structural remodelCongestive heart failure (CHF) is a particularly common ing increases the ability of atria to sustain AF [6] . cause of sustained atrial fibrillation (AF) encountered in
The importance of the renin-angiotensin system in the clinical practice [1] [2] [3] [4] [5] [6] . In patients with symptomatic heart pathophysiology of ventricular remodeling and heart failfailure, the prevalence of AF ranges from 10 to 30%, with ure has been extensively described [9] . Angiotensin-conthe highest incidence among those with the most severe verting enzyme (ACE) inhibitors attenuate left ventricular heart failure [4, 5] . On the other hand, AF promotes heart remodeling after myocardial infarction, and improve venfailure: in patients with CHF, cardiac index and peak tricular performance, symptoms, and prognosis in patients exercise oxygen consumption decline and functional class with left ventricular dysfunction. More recently, one study worsens when AF occurs [7] . Experimental CHF induced showed that the ACE inhibitor trandolapril reduced the by rapid ventricular pacing produces abnormal local atrial incidence of AF in patients with systolic dysfunction after conduction properties associated with atrial structural myocardial infarction [10] . We have recently shown that ACE inhibition reduces extracellular signal-related kinase (ERK) activation and atrial remodeling in experimental CHF [11] . However, the effects of ACE inhibition on areas in both cardiac systole (defined as the largest) and CHF-induced changes in atrial functional remodeling in cardiac diastole (defined as the smallest) were measured in relationship to AF promotion have not been evaluated. the apical 4-chamber view. The average of three consecuThus, the purpose of this study was to determine: (1) the tive cardiac cycles were used for each measurement. Atrial relationship between CHF-induced structural and funcfractional area shortening (FAS) was calculated as tional abnormalities of the atria as assessed by echocar-(systolic area2diastolic area) / systolic area3100. diography and histology; (2) whether these abnormalities
In order to validate our measurements, we subjected ten correlate with AF inducibility; and (3) whether the ACE echocardiograms to three repeated readings in a blinded inhibitor enalapril prevents atrial structural and functional fashion, with three consecutive cardiac cycles analyzed abnormalities and attenuates atrial vulnerability to AF in during every reading of each recording. RA areas in cardiac diastole, respectively. Good correlarevised 1996). We used a dog CHF model produced by tions have been previously described between measurerapid right ventricular pacing as previously described [12] .
ments of LA areas and LV end-diastolic pressure [13] . A ventricular pacemaker (model 8084, Medtronic) was Left ventricular (LV) end-diastolic and end-systolic implanted in a subcutaneous pocket in the neck under volumes were measured using the biplane Simpson's pentobarbital anesthesia (30 mg / kg, i.v.) and attached to a method of discs. The LV ejection fraction was calculated as pacing lead in the right ventricular (RV) apex. The the difference between both volumes divided by the LV pacemaker was programmed to capture the RV at 240 end-diastolic volume times 100. beats / min (bpm) for 3 weeks, followed by 2 weeks at 220 bpm, to diminish early death from severe heart failure.
2.3. AF inducibility and AF duration assessment CHF was established by clinical signs (lethargy, dyspnea and edema) and confirmed by hemodynamic measurements After 5 weeks of RV pacing, the dogs were anesthetized and echocardiographic studies. Twenty mongrel dogs were with morphine (2 mg / kg, s.c.) and a-chloralose (120 randomized to the enalapril (n510) or to the control group mg / kg, i.v., followed by 29.25 mg / kg / h) and ventilated to (n510). The dosage of enalapril was 2 mg / kg / day, p.o., maintain physiological arterial blood gases. A median started on the day of pacing and given for 5 weeks.
sternotomy was performed. The implanted pacemaker was deactivated, and five silicon sheets containing 240 bipolar 2.2. Transthoracic echocardiography electrodes were attached. Stimulation and recording were performed as previously described [6, 14] . The effective Serial transthoracic echocardiographic studies were perrefractory period (ERP) was measured at left atrial and formed at baseline (n510 for each group) and after 1 week right atrial appendages, with 15 basic (S1) stimuli fol-(n510 for each group), 2 weeks (n59 in controls; n58 in lowed by a premature (S2) stimulus, with S1S2 decreasing enalapril group) and 5 weeks (n58 in controls; n59 in by 5-ms decrements. The ERP was defined as the longest enalapril group) of pacing. Dogs were placed in left lateral S1S2 interval that failed to produce a propagated response. decubitus position, and sedated with Atravet (0.07 mg / kg) Conduction velocity was measured in the right and left and buprenorphine (0.009 mg / kg) i.m. for serial echatrial free wall after 2 min at each basic cycle length as ocardiographic examinations. Each examination was perpreviously described [6] . AF was induced by premature formed with the pacemaker off and with the dog in sinus stimuli and burst pacing, with up to three consecutive rhythm. We used a 2.5-MHz phased-array transducer and a extrastimuli at a basic cycle length of 360 ms and then standard echocardiographic system (Hewlett-Packard, Anatrial burst pacing of 10 Hz for 1-10 s. AF was considered dover, MA, USA). The apical 4-and 2-chamber views sustained if it required electrical cardioversion for terminawere obtained and recorded on videotape for off-line tion (cardioversion was never performed until $30 min measurements. Special care was taken to obtain similar had passed since AF onset). To estimate the mean duration imaging planes on serial examinations. The operator and of AF, AF was induced ten times if AF duration was ,20 investigator were blinded to treatment assignment during min, and five times if AF lasted between 20 and 30 min. the whole study course.
When electrical cardioversion was applied, a 30-min rest For both the left atrium (LA) and right atrium (RA), period was allowed before the experiment was continued. 
Statistical analysis
All data are expressed as mean6S.D., except in figures (for which 95% confidence intervals are shown). To analyze evolution over time of variables studied, mixedmodel repeated-measures analysis of covariance controlling for the baseline value [16] were used to extract the group3time interaction and the time and group main effects. When the group3time interaction was significant, which means that groups showed a significant difference in evolution, slice effect (also known as simple effect) [17] analyses were performed to evaluate differences among groups at each time level and to test the evolution of each group. These analyses were performed with the MIXED procedure of SAS 6.12 to handle missing data. Pearson's correlation coefficient was used to evaluate the relation between atrial variables and AF duration. A P value ,0.05 was considered statistically significant.
Results
There was one death (at 2 weeks) in the enalapril group and two deaths (one at 2 weeks and one at 5 weeks) in the controls due to severe heart failure. There was one pacemaker failure at 2 weeks in the enalapril group, which was corrected and the dog paced up to 5-week follow-up. Mean AF duration was not recorded in two dogs in the enalapril group and one dog in the control group. but only by 7% (from 33.063.9 to 30.067.6%, P50.253) in the enalapril group (P50.02 for EN versus controls).
Echocardiographic results
LV end-diastolic volume at baseline was 73.9618.8 ml in enalapril-treated dogs and 78.5627.1 ml in the control dogs (P5NS) and increased to 117.8638.8 and 134.7634.4 ml at 5 weeks (P50.18 for enalapril versus controls). In contrast, LV end-systolic volume was 30.266.9 and 32.2611.7 ml in the enalapril and control groups at baseline (P5NS) but increased respectively to 69.1632.1 and 92.1625.3 ml at 5-week restudy (P50.06, enalapril versus controls). As a result, LV ejection fraction decreased by 25% (from 58.763.7 to 43.068.6%) in enalapril dogs and by 47% (from 59.363.9 to 31.867.8%) in controls (P50.005, enalapril vs. controls).
Hemodynamic and histologic measurements
significantly reduced by therapy, from 11.261.6% in the LV end-diastolic pressure at 5 weeks was 2161 mmHg control group to 8.360.7% in the enalapril group (P5 in control dogs and 1661 mmHg in enalapril-treated dogs 0.008). Atrial fibrosis was highly correlated with LA FAS (P50.001). Similarly, mean LA pressure was 1961 and at 5 weeks (r520.77, P,0.01) and with the decrease in 1461 mmHg in the control and enalapril groups, respec-LA FAS (r50.85, P,0.01) from baseline to restudy. tively (P50.001). Enalapril was also associated with an increase in systolic blood pressure (10464 vs. 11763 3.3. Electrophysiological assessment mmHg, P50.05). The percentage of atrial fibrosis was AF duration at the end of the study was significantly different between treatment groups. Mean AF duration was 138683 s in the enalapril group and 7206461 s in the control group at 5-week follow-up (P50.001). AF duration correlated with atrial systolic and diastolic areas at 5-week restudy, with r values of 0.64 and 0.78 for LA and 0.66 and 0.77 for RA (P#0.01 for all correlations, Fig. 2 ). Negative correlations were observed between AF duration and atrial FAS at 5 weeks for both the LA (r520.79) and RA (r520.71) (P,0.01 for both, Fig. 3 ). AF duration was also correlated with the decrease over the study course of both LA and RA FAS (r50.78 and 0.77, respectively, P#0.001 for each, Fig. 4) .
In contrast, enalapril did not have an effect, when compared to placebo, on effective refractory period It has been well established that the renin-angiotensin (AT) system is important in the process of ventricular remodeling associated with CHF [9] . Furthermore, ACE 4. Discussion inhibition and AT-1 receptor blockade prevent collagen accumulation in the non-infarcted myocardium after The results of this study show that experimental CHF myocardial infarction in rats [21, 22] . The fibrotic abnorcreates substantial atrial structural and functional remodelmalities associated with isoproterenol-induced CHF are ing as assessed by echocardiography, with increased atrial also limited by AT-1 receptor inhibition [23] . Finally, dimensions and decreased fractional area shortening. Both AT-II has been shown to promote collagen synthesis by atrial structural and functional remodeling correlated with cultured fibroblasts and to reduce collagenase activity [24] . vulnerability to AF in the setting of CHF. We also found
The signal transduction systems responsible for the atrial that enalapril significantly attenuated both atrial functional remodeling and fibrosis associated with AF are not well remodeling, with much less LA and RA FAS decrease over known. AT-1 receptors have been shown to be downreguthe study course in dogs treated with the ACE inhibitor lated and AT-2 receptors upregulated in patients with AF, than in controls, and atrial fibrosis. and the expression of ACE was found to be increased [25, 26] . We have shown atrial MAP kinase activation in 4.
Atrial remodeling and fibrosis in experimental CHF
CHF-related AF remodeling, with ERK appearing parand AF ticularly important as a target of the renin-AT system [11] . In addition to attenuating FAS decrease in both atria and Power et al. [18] reported an approximately 100% reducing atrial fibrosis, enalapril reduced AF duration in increase in LA cross-sectional area obtained from a longexperimental CHF in the present study. Our results support axis view in diastole, in a 6-week right ventricular pacing those obtained with another ACE inhibitor, trandolapril, ovine CHF model. The increase in LA area obtained in the which was shown to decrease the incidence of AF in apical 4-chamber view in cardiac diastole in our 5-week patients with LV dysfunction [10] . ventricular pacing CHF dog model was of a similar order (80% in the control group). Our study differed from that of 4.3. Potential clinical relevance Power et al. in that we also analyzed atrial systolic area, introduced FAS to this model, related atrial structural and Currently used antiarrhythmic agents to prevent AF alter functional changes to AF duration, and evaluated the atrial electrophysiological properties but are associated effects of enalapril. Echocardiographic characteristics of with the risk of potentially lethal proarrhythmia. ACE the RA had also not been described in Power's and other inhibition is a potentially appealing approach to treating previous studies [6, 12, 18] . In addition, we have shown the AF associated with CHF, because of the lack of potential relation between echocardiographic and histologic proarrhythmic effects. Although most CHF patients who changes. Indeed, the decrease in atrial FAS was highly can tolerate it are treated with an ACE inhibitor, dosages correlated with the extent of atrial fibrosis in our study.
used are frequently small [27] . Our study may provide the Marked atrial interstitial fibrosis is an important feature impetus for studying the clinical value of ACE inhibitors of AF associated with CHF [6, 19, 20] . In contrast to used at high dosages or in combination with an AT-1 chronic atrial tachycardia, which promotes AF maintereceptor blocker to prevent CHF-induced AF. ACE innance by reducing the wavelength for reentry and increashibitors may also be effective at preventing AF in other ing the regional disparity of refractoriness, CHF does not settings, such as hypertension, rheumatic valve disease and alter these variables in a fashion that would be expected to the aging process, if they can be shown to be associated favor AF [6] . Rather, the key changes in atrial elecwith a similar substrate. Whether interfering with the trophysiology caused by heart failure appear to involve renin-angiotensin system can reverse arrhythmogenic atrialterations in local atrial conduction properties caused by al remodeling and fibrosis once established is not known. atrial structural remodeling and interstitial fibrosis [6] .
Brilla et al. recently demonstrated that lisinopril could These abnormalities represent the substrate that increases induce regression of ventricular fibrosis in patients with the atrial ability to sustain fibrillation in the failing heart. hypertensive heart disease [28] . In contrast, captopril did Our observation in the present study of a good correlation not reduce myocardial fibrosis when therapy was begun between atrial structural and functional remodeling on after CHF had developed in spontaneously hypertensive echocardiography and AF duration in CHF dogs is conrats [29] . Serial echocardiographic examinations in the sistent with this notion and supports the rationale for same animals over time could uniquely demonstrate intervening at the level of the structural substrate in order whether ACE inhibition can induce reverse remodeling of to prevent AF. the atria. In conclusion, our results indicate a role for the
